Robert Mownn, PharmD

) is an oral, targeted therapy approved by the FDA for 3 cancer indications,

 with the most recent approval for use as adjuvant therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.

 Lung cancer is currently the leading cause of cancer-related death worldwide, with an estimated 1.8 million deaths in 2020 and more than 2.2 million newly diagnosed cases.

 Osimertinib therapy may assist patients with lung cancer.

The FDA granted accelerated approval for osimertinib on November 16, 2015, for patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

 The FDA granted osimertinib full approval on March 30, 2017.

Full FDA approval was based on the phase 3 AURA3 trial (NCT012151981), which showcased that in patients with prior radiotherapy within 6 months (n=23), overall response rate (ORR) was 64% with osimertinib and 22% with platinum-pemetrexed. ORR among patients without prior radiotherapy or radiotherapy greater than 6 months prior to randomization (n=93) was 21% and 5%, respectively. Additionally, an improvement in investigator-assessed progression-free survival was observed ([HR], 0.30; 95% [CI], 0.23-0.41; P = 0.001).

Additional cancers treated by osimertinib include the following:

EGFR exon 19 deletions or exon 21 L858R mutations.

As detected in tumor specimen by an approved test.

As detected in tumor or plasma specimen by an approved test.

Osimertinib is a TKI of the EGFR domain that binds irreversibly to specific forms of EGFR mutants (T790M, L858R, and exon 19 deletions) at roughly 9 times greater relative ligand potency than wild type. This selectively inhibits EGFR-meditated uncontrolled growth of cancer cells and cell signaling, consequently decreasing tumor growth and spread.

Osimertinib is dosed as an 80 mg oral tablet, taken with or without food, for patients with select EGFR mutations.

When osimertinib is concomitantly taken with strong CYP3A4 inducers, the labeling recommends increasing the dosage to 160 mg daily for all FDA-approved indications and to resume to the original 80 mg daily only after a 3-week washout from the strong CYP3A4 inducer has occurred.

Warnings, Precautions, and Patient Counseling Points

Osimertinib can cause severe, life threatening complications involving lung inflammation, fatal arrhythmias, serious rashes, and fulminant diarrhea. Osimertinib can be associated with leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough.

It is essential that pharmacists monitor and educate their patients about osimertinib’s drug-related risks and adverse effects (AEs), especially any dermatological AEs, such as rash, because this can progress very rapidly with no recourse.

In the presence of AEs, pharmacists suggest treatment modifications to ensure patient safety (see 

Table 2.: Dosage Modifications for Osimertinib

No data are available on osimertinib use in pregnant women; however, animal models suggest that molecules targeting the EGFRs, such as osimertinib, are expected to cause fetal harm.

Inform women of reproductive potential of the possible risk of fetal harm.

Instruct female patients to notify their health care providers of a known or suspected pregnancy and to use effective contraception during osimertinib treatment and for 6 weeks after the last dose.

Male patients with female partners should use effective contraception during osimertinib treatment and for 16 weeks after the last dose.

Definitive data on whether osimertinib can cross into breast milk or its potential for unintended effects on the child are lacking. Because of the risk of severe AEs in the nursing infant, female patients should be counseled to avoid breastfeeding during treatment and for 2 weeks after the last dose.

is a pharmacist and the Sterile Products Coordinator at St. Vincent’s Medical Center in Connecticut

Osimertinib. Prescribing information. AstraZeneca; 2021. Accessed December 20, 2021. 

https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/52503580-1192-44f7-a05e-5743159ed19b/52503580-1192-44f7-a05e-5743159ed19b_viewable_rendition__v.pdf

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations [News release]. FDA. May 29, 2020. Accessed December 20, 2021. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations

Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71: 209-249. 

TAGRISSO™ (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer [News release] AstraZeneca. Novemeber 13, 2015. Accessed December 20, 2021. https://www.astrazeneca.com/media-centre/press-releases/2015/TAGRISSO-AZD9291-approved-by-the-US-FDA-for-patients-with-EGFR-T790M-mutation-positive-metastatic-non-small-cell-lung-cancer-13112015.html#!

Osimertinib (TAGRISSO) [New release]. FDA. March 30, 2017. Accessed December 20, 2021. 

https://www.fda.gov/drugs/resources-information-approved-drugs/osimertinib-tagrisso

FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations [News release]. FDA. April 18, 2018. Accessed December 20, 2021. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations

Articles

Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications. 

Oncology Overview: Discovering the Therapeutic Value of Osimertinib Targeted Therapy

Although treatment outcomes for patients with breast cancer have improved in recent years, data have shown that 1 in 8 women is likely to develop breast cancer in their lifetime.

 In 2021 alone, the United States recorded 281,550 new cases of invasive breast cancer, 49,290 new cases of noninvasive breast cancer, and 43,600 deaths from the disease.

 Currently, the evolving treatment approaches center on manipulating and targeting each tumor’s molecular identity to effectively treat the disease.

With the use of more sensitive screening protocols and sophisticated molecular testing, survival rates of patients with breast cancer are favorable. When breast cancer is localized, survival rates can approach 99%; when the cancer is regional (eg, metastasis to neighboring/surrounding tissues), survival rates are approximately 86%.

However, when cancer metastasizes to the lung, liver, bone, or brain, survival rates for patients with breast cancer drop to 28%. For this reason, early detection, prompt treatment, individualized therapy, and more tolerable and effective regimens are crucial to improve patient outcomes.

The majority (approximately 72%) of breast cancers are hormone sensitive (hormone receptor [HR]+/HER2-).

 The second most common subtype (approxi- mately 13%) is aggressive triple-negative breast cancer (TNBC, or HR-/HER2-), followed by hormone-sensitive/HER2- sensitive breast cancer (HR+/HER2+) at approximately 10%, and HR-/HER2+ breast cancer at 5%.

When directing next steps in a treatment plan, staging is often the most important factor. Once oncologists determine the stage and main genotype, the clinical team will work collaboratively with the patient to decide the best treatment strategy.

Clinicians use a few core therapies alone or, for greater efficacy, in combination with another therapy for breast cancer treatment (See Table 1

 provides further examples of breast cancer thera- pies used for treatment.

Patients with early-stage breast cancer (stages 0, I, II, or III) generally undergo primary surgery followed by adjuvant treatment. When the cancer is late, advanced, or metastatic at stage IV, surgical interventions are usually not an option and medication therapy is the mainstay.

Molecular targets and potential future changes for combatting breast cancer are as follows:

—Recent studies found that when started early, HR regimens can be as effective as traditional chemotherapy options and minimize adverse events.

—The success of trastuzumab (Herceptin; Genentech USA, Inc) and pertuzumab (Perjeta; Genentech USA, Inc) has sparked interest in exploiting HER2 as a target. Recently, the FDA approved margetuximab-cmkb (Margenza; MacroGenics, Inc), which may be effective for select patients as well.

 Additionally, cytotoxic drug conjugates have made significant progress, with more agents undergoing clinical trials.

—The immunotherapy space, including investiga- tion into the PD-1/PD-L1 pathway, is exploding due to findings that it may deter or treat brain metastases.

—Mutations such as BRCA1/2 and PALB2 have been identified as PARP inhibitor targets, especially in the treat- ment of metastatic TNBC.

 (CDK4/6)—More research efforts are combining CDK4/6 agents with endo- crine therapies in metastatic HR+ breast cancers, which may enable patients to avoid traditional chemotherapy if proven effective.

 (TKIs)—Oral medications such as tucatinib (Tukysa; Seagen Inc), lapatinib (Tykerb; Novartis Pharmaceuticals Corporation), neratinib (Nerlynx; Puma Biotechnology, Inc), and newly developed TKIs may protect against brain metastases and have a role in HER2+ meta- static breast cancer treatment.

—Alpelisib (Piqray; Novartis Pharmaceuticals Corpora- tion) has shown promise in the SOLAR-1 (NCT02437318)11 and BYLieve (NCT03056755)12 clinical trials and may benefit patients with PIK3CA-mutated tumors or HR+ metastatic breast cancer.

—Antiangiogenesis drugs such as bevacizumab (Avastin; Genentech USA, Inc) have returned to clinical trials combined with chemotherapy/immunotherapy, which may have potential in the treatment of metastatic HR+ breast cancer.

 (histone deacetylase)—Entinostat and tucidinostat are both in clinical trials for various cancers. Tucidinostat is also currently recruiting for a phase 2 clinical trial for metastatic HR+ breast cancer treatment.

 (tumor-associated calcium signal transducer 2)—The FDA approved sacituzumab govitecan-hziy (Trodelvy; Gilead Sciences, Inc) in 2021 for the treatment of metastatic disease in TNBC; currently, more agents in this novel class are being developed, studied, and assessed.

Chemotherapy often has off-target effects due to its cytotoxic nature, but it still has a place in treatment as a monotherapy or in a combination treatment. Moving forward, investigators are formulating chemotherapy in more tolerable, convenient, and effective vehicles such as oral dosage forms or drug-antibody conjugates with targeted payload deliveries that exhibit less off-target effects.

During the clinical decision-making process around treatments, breast cancer subtypes have a direct impact on therapy options. Table 3 summarizes treatment approaches for the common HR+/ HER2- subtype.

Most breast cancer is hormone sensitive, which implies that both the estrogen receptor and progesterone receptor can be targeted to inhibit tumor growth.

Additionally, shifting from traditional chemotherapy to a more effective targeted endocrine therapy, especially when resistance to endocrine therapy develops, can have a significant impact. Comparative research, early detection, and an optimized medication repertoire may make this shift a possibility soon. Regardless, results from the TAILORx trial (NCT00310180) and guidance from the National Comprehensive Cancer Network support the integration of chemotherapy and endocrine treatment when recurrence potential is high.

Patients with both the HR+ subtype and HER2+ subtype (triple positive) can receive all the endocrine therapy options shown in Table 3; these patients can also receive all chemotherapeutic options in addition to HER2+ guided treatment plans.

 In Table 4, treatment approaches for the HER2+ subtype are included.

In HR+/HER2+ patients, trastuzumab can be combined with fulvestrant or aromatase inhibitors (AIs) with or without lapatinib, and AIs can be used with lapatinib and without trastuzumab. However, endocrine therapy is not indicated for HR- subtypes.

Cancers that lack estrogen receptor, progesterone receptor, or HER2 are difficult. Because TNBC lacks targets, the most effective treatments for early and late stage are identical to options found in Table 3.

In any stage, clinicians may use adjunctive therapy options, such as atezolizumab (Tecentriq; Genentech USA, Inc) with albumin-bound paclitaxel (with PD-L1 expression), pembrolizumab (Keytruda; Merck Sharp & Dohme Corp; with PD-1 expression), platinums, capecitabine, or sacituzumab govitecan-hziy.

The growing trend is targeted, safe, and effective therapy that aligns with the patient’s goals. Currently, there are unmet needs for therapy options that target HER2, for antibody-drug conjugates, and for more advanced-stage therapies for those with TNBC. However, it seems likely that in the future, we can expect to see more effective oral therapy options for HER+ cases.

Today, research is primarily focusing on reducing progression, propagation, and treatment-resistant genotypes; however, clinicians should remain open to the de-escalation of chemotherapy and/or invasive surgical procedures because other options may be as effective or superior.

, is a pharmacist and sterile products coordinator at St Vincent’s Medical Center in Bridgeport, Connecticut. He is a graduate of
the University of Connecticut’s School of Pharmacy.

Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 

. 2021;71(3):209-249. doi:10.3322/caac.21660

Breast cancer statistics. Susan G. Komen. Accessed December 9, 2021. 

https://www.komen.org/breast-cancer/facts-statistics/breast-cancer-statistics/

American Cancer Society. Cancer facts & figures 2021. Accessed December 9, 2021. 

https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

NCCN. Clinical Practice Guidelines in Oncology. Breast cancer, version 1.2022. Accessed December 9, 2021. 

https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf

Martí C, Sánchez-Méndez JI. The present and future of neoadjuvant endocrine therapy for breast cancer treatment. 

 2021;13(11):2538. doi:10.3390/cancers13112538

FDA approves margetuximab for metastatic HER2-positive breast cancer. FDA. Updated December 17, 2020. Accessed January 13, 2022. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer

Kim JS, Kim IA. Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. 

. 2020;12:175883592093611. doi:10.1177/1758835920936117

Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. 

. 2020;38(36):4274-4282. doi:10.1200/jco.20.02151

Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. 

. 2020;21(6):763-775. doi:10.1016/s1470-2045(20)30112-1

Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. 

 2021;13(12):2927. doi:10.3390/cancers13122927

André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. 

. 2021;32(2):208-217. doi:10.1016/j.annonc.2020.11.011

Turner S, Chia S, Kanakamedala H, et al. Effectiveness of alpelisib + fulvestrant compared with real-world standard treatment among patients with HR+, HER2-, PIK3CA-mutated breast cancer. 

. 2021;26(7):e1133-e1142. doi:10.1002/onco.13804

A phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for locally advanced unresectable or metastatic hormone receptor-positive HER2 Negative Breast Cancer (AMBITION). ClinicalTrials.gov. Updated March 3, 2021. Accessed December 9, 2021. 

https://clinicaltrials.gov/ct2/show/results/NCT04732598

Tucidinostat and fulvestrant in hormone-receptor positive advanced breast cancer. ClinicalTrials.gov. Updated August 11, 2021. Accessed December 9, 2021. 

https://clinicaltrials.gov/ct2/show/NCT04999540

FDA grants regular approval to sacituzumab govitecan for TNBC. FDA. Updated April 8, 2021. Accessed December 9, 2021. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. 

. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710

Breast cancer metastasis to brain: symptoms and diagnosis. BreastCancer.org. Updated June 20, 2019. Accessed December 9, 2021. 

https://www.breastcancer.org/symptoms/types/recur_metast/metastic/brain

Masuda N, Lee SJ, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. 

. 2017;376(22):2147-2159. doi:10.1056/nejmoa1612645

An emerging focus is aligning targeted, safe, and effective therapies with patient goals.